Nyxoah reports Q3 EPS (EUR 0.63) vs. (EUR 0.50) last year

Reports Q3 revenue EUR 1.97M vs. EUR 1.27M last year. “The first weeks post FDA approval have been a huge success. We already completed the first implants in September. The response from physicians has been overwhelmingly positive, driven by the excitement of finally having real optionality in hypoglossal nerve stimulation for OSA patients,” commented Olivier Taelman, Nyxoah’s (NYXH) CEO. “We also secured reimbursement and generate the first U.S. revenue within the first month post FDA approval. The financing transaction announced today will support our sustained growth in the U.S. market. The momentum and enthusiasm couldn’t be greater.”